This Week in Psychedelics
Jan 7, 2026
•
13 min read
[5-min read] Real-world psilocybin therapy study tempers expectations for treatment-resistant depression.
Dec 31, 2025
10 min read
[4-min read] 2025's biggest psychedelic shifts and our predictions for 2026.
Dec 24, 2025
[5-min read] Psychedelics stocks rally after cannabis rescheduling order.
Dec 17, 2025
11 min read
[5-min read] Psilocybin reduces symptoms of OCD in 48 hours.
Dec 10, 2025
[5-min read] Researchers conduct first trial of MDMA-assisted therapy for depression.
Dec 3, 2025
12 min read
[5-min read] DEA announces steep production quota increases for multiple psychedelics.
Nov 26, 2025
[5-min read] Study finds psychedelic decriminalization hasn't increased ER visits.
Nov 19, 2025
[5-min read] AtaiBeckley posts open-label extension results for its 5-MeO-DMT formulation.
Nov 12, 2025
[5-min read] Maryland task force proposes three-phased approach to psychedelic legalization.
Nov 5, 2025
[5-min read] Arizona-funded clinical trial will test whole psilocybin mushrooms for PTSD.
Oct 29, 2025
[5-min read] Ketamine company receives one of nine FDA Commissioner's National Priority Vouchers.
Oct 22, 2025
14 min read
[5-min read] atai receives FDA's seventh breakthrough therapy designation for a psychedelic drug.
Oct 15, 2025
[5-min read] Crossover trial examines the key differences between MDMA and MDA.
Oct 8, 2025
[6-min read] New research reveals how psilocybin breaks the pain-depression cycle.
Oct 1, 2025
[5-min read] Osmind shares first study of real-world outcomes from Oregon Psilocybin Services.
Sep 24, 2025
[5-min read] NIH awards atai Life Sciences $11.4 million to develop non-hallucinogenic psychedelics.
Sep 17, 2025
[5-min read] International psychedelic drugmaker files for US Initial Public Offering.
Sep 10, 2025
[5-min read] MindMed publishes full results from its Phase 2b trial of LSD for anxiety.
Sep 3, 2025
[5-min read] Brain imaging study reveals the connection between high-ventilation breathwork and mystical experiences.
Aug 27, 2025
[5-min read] New study explores trauma recall during psychedelic experiences and extended difficulties.
Aug 20, 2025
[5-min read] Reunion Neuroscience shares results from Phase 2 postpartum depression trial.
Aug 13, 2025
[5-min read] First-of-its-kind study examines affordability and feasibility in group psilocybin therapy.
Aug 6, 2025
[5-min read] Germany becomes the first EU country to offer legal psychedelic access.
Jul 30, 2025
[5-min read] Large-scale study suggests psychedelics outperform prescription meds for eating disorders.
Jul 23, 2025
[5-min read] First-of-its-kind study investigates psychedelic retreats as a holistic therapy for veteran reintegration.
